Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7S7D

STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC SULFO-MLL PEPTIDE ANALOG

Summary for 7S7D
Entry DOI10.2210/pdb7s7d/pdb
DescriptorHLA class I histocompatibility antigen, B-7 alpha chain, Beta-2-microglobulin, MLL cleavage product N320, ... (5 entities in total)
Functional Keywordshla, mll peptide, mhc-i, hla-b*07:02, hla-b7, immunity, immune system, phosphopeptide, sulfo analog, cancer
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains3
Total formula weight45226.85
Authors
Primary citationPatskovsky, Y.,Natarajan, A.,Patskovska, L.,Nyovanie, S.,Joshi, B.,Morin, B.,Brittsan, C.,Huber, O.,Gordon, S.,Michelet, X.,Schmitzberger, F.,Stein, R.B.,Findeis, M.A.,Hurwitz, A.,Van Dijk, M.,Chantzoura, E.,Yague, A.S.,Pollack Smith, D.,Buell, J.S.,Underwood, D.,Krogsgaard, M.
Molecular mechanism of phosphopeptide neoantigen immunogenicity.
Nat Commun, 14:3763-3763, 2023
Cited by
PubMed Abstract: Altered protein phosphorylation in cancer cells often leads to surface presentation of phosphopeptide neoantigens. However, their role in cancer immunogenicity remains unclear. Here we describe a mechanism by which an HLA-B*0702-specific acute myeloid leukemia phosphoneoantigen, pMLL (EPR(pS)PSHSM), is recognized by a cognate T cell receptor named TCR27, a candidate for cancer immunotherapy. We show that the replacement of phosphoserine P with serine or phosphomimetics does not affect pMHC conformation or peptide-MHC affinity but abrogates TCR27-dependent T cell activation and weakens binding between TCR27 and pMHC. Here we describe the crystal structures for TCR27 and cognate pMHC, map of the interface produced by nuclear magnetic resonance, and a ternary complex generated using information-driven protein docking. Our data show that non-covalent interactions between the epitope phosphate group and TCR27 are crucial for TCR specificity. This study supports development of new treatment options for cancer patients through target expansion and TCR optimization.
PubMed: 37353482
DOI: 10.1038/s41467-023-39425-1
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.56 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon